on October 23, 2008
Published online before print October 23, 2008, doi: 10.1161/STROKEAHA.108.518621
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 29, 2008
From Columbia University (L.M.), New York, NY; the University of California, San Francisco (D.G.), San Francisco, Calif; the University of California–San Diego (E.B.-C.), La Jolla, Calif; Royal Brompton Hospital and Imperial College (P.C.), London, UK; Emory University (N.W.), Atlanta, Ga; the University of Toronto (B.L.A.), Toronto, Ontario, Canada; Keck School of Medicine (A.P.-H.), University of Southern California, Los Angeles, Calif; Eli Lilly and Company (M.J.G., S.A.D., M.A.-A.), Indianapolis, Ind; and Brussels Free University (M.K.), Brussels, Belgium. * To whom correspondence should be addressed. E-mail: ljm10{at}columbia.edu; lmr2@columbia.edu.
Background and Purpose—Raloxifene, a selective estrogen receptor modulator, reduces risk of invasive breast cancer and osteoporosis, but the effect on risk for stroke and venous thromboembolism in different patient subgroups is not established. The purpose of this analysis was to evaluate the effect of raloxifene on the incidence of all strokes, stroke deaths, and venous thromboembolic events according to participant subgroups. Methods—This was a secondary end point analysis of an international, randomized, placebo-controlled clinical trial of 10 101 postmenopausal women with or at increased risk of coronary heart disease followed a median of 5.6 years. Strokes, venous thromboembolic events, and deaths were adjudicated by expert centralized committees. Strokes were categorized as ischemic, hemorrhagic, or undetermined and venous thromboembolic events were subclassified. Results—The incidences of all strokes did not differ between raloxifene (incidence rate per 100 woman-years=0.95) and placebo (incidence rate=0.86) treatment groups (P=0.30). In women assigned raloxifene versus placebo, there was a higher incidence of fatal strokes (incidence rates=0.22 and 0.15, respectively, P=0.0499) and venous thromboembolic events (incidence rates=0.39 and 0.27, respectively, P=0.02). No significant subgroup interactions were found except that there was a higher incidence of stroke associated with raloxifene use among current smokers. Conclusions—In postmenopausal women at increased risk for coronary events, the incidences of venous thromboembolism and fatal stroke but not all strokes were higher in those assigned raloxifene versus placebo. Raloxifene's effect did not differ across subgroups, except that the risk of stroke differed by smoking status. Treatment decisions about raloxifene should be based on a balance of projected absolute risks and benefits.
Revised on May 29, 2008
Accepted on June 4, 2008
Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease
Lori Mosca MD, PhD*;
Key words: clinical trial • stroke • venous thromboembolism